Company Summary - GlaxoSmithKline PLC (LSE:GSK)
1,411.00p
2.00p
(0.14%)
FTSE 100 Pharmaceuticals & BiotechnologyMarket cap: £71,281.566m
NEW Explore our new and improved report for GlaxoSmithKline PLC >>
Gain access to various premium features such as detailed information on financial reports, broker forecasts, directors and shareholders information.
Summary
Engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products
| Financials - Special Div (7/2/2012) | ||
|---|---|---|
| Turnover | £m | 0 |
| Pre-tax Profit | £m | 0 |
| EPS | p | 0.00 |
| DPS | p | 0.00 |
| Director | Board Role |
|---|---|
| Sir Christopher Gent | Chairman |
| Andrew Witty | Chief Executive |
| Simon Dingemans | Finance Director |
Products Brands & Subsidiaries
Products & Brands
Agenerase; Altabax; Aquafresh; Arixtra; Arzerra; Augmentin; Avandamet; Avandia; Avodart; Benlysta; Biotene; Boniva/Bonviva...
Subsidiaries
Glaxo Operations UK Ltd; The Wellcome Foundation Ltd; Glaxo Group Ltd; Wellcome Ltd; SmithKline Beecham (Cork) Ltd...
Broker Sentiment (9 brokers)
Strong SellStrong Buy
| Heading | Date |
|---|---|
| Transaction in Own Shares | 10/02/2012 |
| Director/PDMR Shareholding | 10/02/2012 |
| Director/PDMR Shareholding | 10/02/2012 |
For more information
and investor relations, visit the
GlaxoSmithKline PLC company website: